

For Immediate Release

Len Post joins the Orphagen Board of Directors

San Diego, March 17, 2007--Len Post, former Senior Vice President of Onyx Pharmaceuticals, has been appointed to the Orphagen Board of Directors, Orphagen's CEO, Scott Thacher, announced today. Dr. Post has taken leadership positions in pharmaceutical R&D over the last 20 years, first as Vice President at Upjohn Pharmaceuticals and later as Vice President of Research & Development at Parke-Davis. At Onyx, Dr. Post successfully directed the development team that obtained FDA approval for Nexavar in a partnership with Bayer A.G. In addition to his senior executive experience, Dr. Post is the author of more than 50 scientific publications.

Scott Thacher, CEO of Orphagen said, "as Orphagen has started to move its discovery programs into the hit-to-lead and lead optimization stage, we have been looking for an outstanding executive with strong scientific and drug discovery credentials to join our Board. Len Post is the ideal candidate given his broad experience. Dr. Post will join the Company both as scientific consultant and member of the Board of Directors."

Contact: Scott Thacher

Phone: (858) 481-6191

e-mail: smt@orphagen.com

Orphagen Pharmaceuticals, 11494 Sorrento Valley Road, San Diego, CA 92121